{
    "organizations": [],
    "uuid": "5188763cad116d0f9c7ea4bea80ee6e9d249973c",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/08/globe-newswire-genocea-to-host-fourth-quarter-and-year-end-2017-financial-results-conference-call-webcast-on-february-15-2018-at-9-a-m-et.html",
    "ord_in_thread": 0,
    "title": "Genocea to Host Fourth Quarter and Year End 2017 Financial Results Conference Call & Webcast on February 15, 2018 at 9 a.m. ET",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a conference call and live audio webcast on Thursday, February 15, 2018 at 9:00 a.m. ET to discuss financial results for the fourth quarter and year end 2017. Genocea management will also provide an update on the Company's recent progress and upcoming milestones.\nInterested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and refer to conference ID number 7396178. To join the live webcast, please visit the investor relations section of the Genocea website at http://ir.genocea.com .\nA webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.\nAbout Genocea Biosciences, Inc.\nGenocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLASâ„¢, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea uses ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018. Genocea is exploring strategic alternatives for GEN-003, its Phase 3-ready immunotherapy candidate for the treatment of genital herpes.\nFor media:\nJennifer LaVin\nGenocea Biosciences, Inc.\nO: 207-360-0473\nJennifer.lavin@genocea.com\nFor investors:\nJonathan Poole\nGenocea Biosciences, Inc.\nO: 617-715-7795\njonathan.poole@genocea.com\nSource:Genocea Biosciences, Inc.",
    "published": "2018-02-08T16:00:00.000+02:00",
    "crawled": "2018-02-08T16:55:22.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "cambridge",
        "globe",
        "newswire",
        "genocea",
        "bioscience",
        "nasdaq",
        "gnca",
        "biopharmaceutical",
        "company",
        "developing",
        "neoantigen",
        "cancer",
        "vaccine",
        "today",
        "announced",
        "host",
        "conference",
        "call",
        "live",
        "audio",
        "webcast",
        "thursday",
        "february",
        "et",
        "discus",
        "financial",
        "result",
        "fourth",
        "quarter",
        "year",
        "end",
        "genocea",
        "management",
        "also",
        "provide",
        "update",
        "company",
        "recent",
        "progress",
        "upcoming",
        "milestone",
        "interested",
        "participant",
        "may",
        "access",
        "conference",
        "call",
        "dialing",
        "domestic",
        "international",
        "refer",
        "conference",
        "id",
        "number",
        "join",
        "live",
        "webcast",
        "please",
        "visit",
        "investor",
        "relation",
        "section",
        "genocea",
        "website",
        "http",
        "webcast",
        "replay",
        "available",
        "genocea",
        "website",
        "beginning",
        "approximately",
        "two",
        "hour",
        "event",
        "archived",
        "day",
        "genocea",
        "bioscience",
        "genocea",
        "harnessing",
        "power",
        "cell",
        "immunity",
        "develop",
        "vaccine",
        "immunotherapy",
        "traditional",
        "immunotherapy",
        "discovery",
        "method",
        "largely",
        "used",
        "predictive",
        "method",
        "propose",
        "cell",
        "target",
        "antigen",
        "genocea",
        "successfully",
        "developed",
        "proprietary",
        "technology",
        "platform",
        "identify",
        "clinically",
        "relevant",
        "antigen",
        "cell",
        "based",
        "actual",
        "human",
        "immune",
        "response",
        "genocea",
        "us",
        "atlas",
        "application",
        "develop",
        "neoantigen",
        "cancer",
        "vaccine",
        "also",
        "exploring",
        "partnership",
        "opportunity",
        "general",
        "cancer",
        "vaccine",
        "vaccine",
        "targeting",
        "cancer",
        "caused",
        "virus",
        "genocea",
        "expects",
        "begin",
        "clinical",
        "development",
        "first",
        "neoantigen",
        "cancer",
        "vaccine",
        "genocea",
        "exploring",
        "strategic",
        "alternative",
        "phase",
        "immunotherapy",
        "candidate",
        "treatment",
        "genital",
        "herpes",
        "medium",
        "jennifer",
        "lavin",
        "genocea",
        "bioscience",
        "investor",
        "jonathan",
        "poole",
        "genocea",
        "bioscience",
        "source",
        "genocea",
        "bioscience",
        "inc"
    ]
}